Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvictotm (lutetium (177Lu) vipivotide tetraxetan ...
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.